Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
Denali Therapeutics Inc. (NASDAQ:DNLI) revealed topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS ...
BioSpace2d
Denali Suffers Another ALS Fail With Phase II/III Flop
Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...
Pharmaceutical Technology10d
Aldesleukin by Iltoo Pharma for Amyotrophic Lateral Sclerosis: Likelihood of Approval
Aldesleukin is under clinical development by Iltoo Pharma and currently in Phase III for Amyotrophic Lateral Sclerosis.
Too Old to Operate20h
Education Moderates Motor-Cognition Relationship in ALS Without Dementia
The following is a summary of “Education moderates the association between motor involvement and executive status in ALS,” published in the December 2024 issue of Neurology by Aiello et al.
EurekAlert!3d
Patient-derived induced pluripotent stem cell organoids for amyotrophic lateral sclerosis drug discovery
Announcing a new publication for Acta Materia Medica journal. Complex biological mechanisms and unidentified therapeutic targets for amyotrophic lateral sclerosis (ALS) significantly hinder the develo ...
Bozeman Daily Chronicle2d
An Israeli TV reporter lost his ability to speak clearly. AI is helping him get back on air
When a renowned Israeli TV journalist lost his ability to speak clearly because of ALS, he thought his career might be over. But now, using artificial-intelligence software ...
Santa Rosa Press Democrat1d
ALS sidelined this Israeli TV journalist. AI is helping him make a comeback.
A renowned Israeli TV journalist who lost his ability to speak clearly because of ALS is returning to the air using artificial-intelligence software that recreates his widely recognized gravelly voice ...